✦ LIBER ✦

The importance of (A) rapid data processing and (B) randomization in phase II trials of cytotoxics in oncology illustrated by the trials of an analogue of cisplatin

✍ Scribed by Roger P. A'Hern; Joan Houghton; Michael Baum; Christopher Franks

Book ID: 119143131
Publisher: Elsevier Science
Year: 1984
Tongue: English
Weight: 69 KB
Volume: 5
Category: Article
ISSN: 0197-2456
DOI: 10.1016/0197-2456(84)90072-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Methotrexate, vinblastine, doxorubicin,

Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group

✍ Bruce J. Roth; George W. Sledge Jr; Stephen D. Williams; Steven C. Meyer; Rafat 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 2 views

Forty-six eligible patients with metastatic breast cancer (MBC) were treated with a combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy. Of 44 patients evaluable for response, 28 (64%) had an objective response, including seven (16%) who had a comp

Phase II trials of cisplatin and piperaz

Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: A gynecologic oncology group study

✍ J.Tate Thigpen; John A. Blessing; Howard D. Homesley; George C. Lewis Jr 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 376 KB

Cisplatin and Pentoxifylline in Advanced

Cisplatin and Pentoxifylline in Advanced or Recurrent Squamous Cell Carcinoma of the Cervix: A Phase II Trial of the Gynecologic Oncology Group

✍ Robert S. Mannel; John A. Blessing; Guy Boike 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 31 KB

Phase II trial of the combination of bry

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study

✍ Farr Nezhat; Scott Wadler; Franco Muggia; John Mandeli; Gary Goldberg; Jamal Rah 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 102 KB

A randomized Phase II trial of echinomyc

A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma : An Eastern Cooperative Oncology Group Study (E1587)

✍ Alex Y. Chang; KyungMann Kim; Hélène Boucher; Philip Bonomi; James A. Stewart; D 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## Background: Patients with metastatic nonsmall cell lung carcinoma (nsclc) usually have a poor prognosis. a chemotherapy regimen containing cisplatin is commonly used for symptom palliation. echinomycin is a potent bifunctional intercalator of double-strand dna; trimetrexate is a new derivative o

The combination of cisplatin, doxorubici

The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma: A phase II randomized trial of the Italian oncology group for clinical research

✍ Vincenzo De Lisi; Giorgio Cocconi; Francesco Angelini; Francesco Cavicchi; Franc 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 2 views

## BACKGROUND. In a randomized Phase I1 study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) comhination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) Combination, in pat